Tempus AI (NASDAQ:TEM) Shares Up 1.8% - Should You Buy?

Tempus AI, Inc. (NASDAQ:TEM - Get Free Report)'s share price traded up 1.8% during mid-day trading on Wednesday . The company traded as high as $48.37 and last traded at $48.05. 2,138,700 shares were traded during mid-day trading, a decline of 59% from the average session volume of 5,252,110 shares. The stock had previously closed at $47.22.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on TEM. Bank of America lifted their target price on shares of Tempus AI from $54.00 to $60.00 and gave the stock a "neutral" rating in a research note on Monday, March 3rd. TD Cowen reissued a "buy" rating and set a $74.00 target price (up previously from $58.00) on shares of Tempus AI in a report on Wednesday, February 5th. Morgan Stanley boosted their price objective on Tempus AI from $50.00 to $60.00 and gave the company an "overweight" rating in a research note on Thursday, March 6th. Piper Sandler cut their target price on Tempus AI from $70.00 to $55.00 and set a "neutral" rating for the company in a research note on Tuesday, March 4th. Finally, William Blair reiterated a "market perform" rating on shares of Tempus AI in a research report on Tuesday, February 25th. Six research analysts have rated the stock with a hold rating and six have given a buy rating to the company. Based on data from MarketBeat, Tempus AI presently has a consensus rating of "Moderate Buy" and an average target price of $61.18.

Tempus AI Stock Down 7.5 %

The company has a current ratio of 2.69, a quick ratio of 2.55 and a debt-to-equity ratio of 8.17. The company has a fifty day moving average price of $58.45 and a 200 day moving average price of $51.51.

Remove Ads

Insider Buying and Selling at Tempus AI

In other Tempus AI news, COO Ryan Fukushima sold 20,000 shares of Tempus AI stock in a transaction dated Tuesday, January 7th. The stock was sold at an average price of $39.61, for a total transaction of $792,200.00. Following the completion of the sale, the chief operating officer now owns 982,442 shares of the company's stock, valued at $38,914,527.62. The trade was a 2.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, major shareholder Bradley A. Keywell sold 170,720 shares of the company's stock in a transaction dated Wednesday, January 15th. The stock was sold at an average price of $35.45, for a total value of $6,052,024.00. Following the completion of the transaction, the insider now owns 15,993,729 shares of the company's stock, valued at $566,977,693.05. The trade was a 1.06 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 5,601,969 shares of company stock worth $317,330,782 over the last three months.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in TEM. The Manufacturers Life Insurance Company boosted its stake in shares of Tempus AI by 10.2% in the 3rd quarter. The Manufacturers Life Insurance Company now owns 29,789 shares of the company's stock valued at $1,686,000 after purchasing an additional 2,765 shares in the last quarter. Captrust Financial Advisors bought a new stake in Tempus AI in the third quarter worth $2,726,000. Benjamin Edwards Inc. purchased a new stake in Tempus AI during the third quarter valued at about $725,000. Stifel Financial Corp bought a new position in shares of Tempus AI during the third quarter valued at about $218,000. Finally, Kovitz Investment Group Partners LLC purchased a new position in shares of Tempus AI in the third quarter worth about $1,367,000. 24.22% of the stock is owned by hedge funds and other institutional investors.

About Tempus AI

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.